Patheon to host drug development seminar

Published: 11-Feb-2013
Research & Development

Scientific leaders to share their experiences and answer questions on strategies for effectively progressing small molecules


Patheon will be hosting a complimentary seminar on ‘Getting Your Drug Through Phase I Early Development Effectively’. In the upcoming seminar, the company has invited three scientific leaders to share their experiences and answer questions on strategies for effectively progressing small molecules through early drug development.

Presentations will be provided by Patheon employees Dr Jon Sutch and Rick Bastin, as well as from Dr Paul Madeley from Synth-Isis. Through case studies and interactive presentations, presenters will discuss early stages of active pharmaceutical ingredient (API) development, formulation strategies and challenges of low solubility and bioavailability. There will also be an opportunity to pose technical questions to the company’s experts through the Ask the Experts round table.

The seminar will be held on Tuesday 19 February at 11.30am – 6pm Central European Time at Patheon’s Milton Park facility in Oxfordshire, UK. Visit Patheon’s website to learn more or register here.

Patheon recently announced its plans to launch the company’s SoluPath program at the Milton Park facility as part of the company’s global strategy to expand early pharmaceutical development services for its customers.

  • Companies:
  • Patheon
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

Read more
In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  3. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  4. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend
Regulatory

Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

Agreement will support Phase II/III studies of Caelum's CAEL-101 in AL amyloidosis
Manufacturing

Thermo Fisher Scientific to acquire leading CDMO, Patheon

The transaction represents a purchase price of approximately $7.2bn
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Now is the time to outsource the management of outsourcing

More than ever before, specialist expertise is being called upon by the pharma industry – from strategy, supply chain and regulatory boutiques through to one-stop CDMOs that provide the whole spectrum of API development to final product production. Susan Birks talked to Patheon about the trends
Manufacturing

Patheon agrees biologics deal with Inhibrx

Initial development work will focus on establishing platform processes for Inhibrx’s cell lines
Research & Development

Patheon expands stability testing capabilities

Company invests US$3m in equipment and talent in its centralised stability testing lab
Manufacturing

Patheon to participate in industry panels at Interphex

Patheon will showcase Patheon OneSource, the industry-leading solution that provides a simplified and customised offering, including both drug substance and drug production services to help clients get to market faster and cost effectively
Subscribe now